Drug‐induced phospholipidosis (PLD) is a lysosomal storage disorder characterized by the
accumulation of phospholipids within the lysosome. This adverse drug effect can occur in …

Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably
cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids …

Drug-induced phospholipidosis (PLD) is characterized by accumulation of phospholipids,
the inducing drugs and lamellar inclusion bodies in the lysosomes of affected tissues. These …

Drug induced phospholipidosis (PLD) is an adverse side effect which can affect registration
of new drug entities. Phospholipids can accumulate in lysosomes, organelles essential in …

Drug-induced phospholipidosis (PLD) is an adaptive histologic alteration that is seen with
various marketed drugs and often encountered during drug development. Various in silico …

Drug-induced phospholipidosis (PL) is an excessive accumulation of phospholipids and
drug in lysosomes. Phospholipidosis signals a change in cell membrane integrity and …

The identification of phospholipidosis (PPL) during preclinical testing in animals is a
recognized problem in the pharmaceutical industry. Depending on the intended indication …

Publisher Summary This chapter focuses on the mechanism and the toxicological
implications of drug-induced phospholipidosis (PLD)—a condition in which drugs cause the …

Phospholipidosis (PLD) is an undesirable potential side-effect of drugs, and cationic
amphiphilic drugs (CADs) represent the main class of PLD inducers. A CADs toxicophore …

Drug-induced phospholipidosis (PLD), characterized by an intracellular accumulation of
phospholipids and formation of concentric lamellar bodies, has raised concerns in the drug …